A successful biotechnology manager must know what to expect during the early stages of a startup and be eager to fight to overcome obstacles. Our experience tells us, for example, that candidates ...

with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation. On balance, at these price levels, VIR stock is attractive, though risky. Vir Biotechnology (NASDAQ ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor (CPI) tislelizumab MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the ...